EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases

Annalisa Addante, Wilfred Raymond, Irina Gitlin, Annabelle Charbit, Xavier Orain, Aaron Wolfe Scheffler, Aditi Kuppe, Julia Duerr iD, Maria Daniltchenko, Marika Drescher, Simon Y Graeber iD, Anne-Marie Healy und 3 weitere

European Respiratory Journal · 2023-05 · 61 (5) · 2202022

DOI: 10.1183/13993003.02022-2022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 20.04.2023. Verfasst von Annalisa Addante und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie …. Hauptthemen laut MEDLINE: Cystic Fibrosis, Lung Diseases, Obstructive. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucin disulfide cross-links mediate pathologic mucus formation in muco-obstructive lung diseases. MUC-031, a novel thiol-modified carbohydrate compound, cleaves disulfides to cause mucolysis. The aim of this study was to determine the mucolytic and therapeutic effects of MUC-031 in sputum from patients with cystic fibrosis (CF) and mice with muco-obstructive lung disease (βENaC-Tg mice).

Methods

We compared the mucolytic efficacy of MUC-031 and existing mucolytics (N-acetylcysteine (NAC) and recombinant human deoxyribonuclease I (rhDNase)) using rheology to measure the elastic modulus (G′) of CF sputum, and we tested effects of MUC-031 on airway mucus plugging, inflammation and survival in βENaC-Tg mice to determine its mucolytic efficacy in vivo .

Results

In CF sputum, compared to the effects of rhDNase and NAC, MUC-031 caused a larger decrease in sputum G′, was faster in decreasing sputum G′ by 50% and caused mucolysis of a larger proportion of sputum samples within 15 min of drug addition. Compared to vehicle control, three treatments with MUC-031 in 1 day in adult βENaC-Tg mice decreased airway mucus content (16.8±3.2 versus 7.5±1.2 nL·mm −2 , p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisLung Diseases, ObstructiveAdultHumansMiceAnimalsExpectorantsSulfhydryl CompoundsAcetylcysteineSputumInflammationCarbohydratesLung

Substanzen

ExpectorantsSulfhydryl CompoundsAcetylcysteineCarbohydrates

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • German Centre for Lung Research (DZL), associated partner, Berlin, Germany.
  • Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland.

ORCID-Profile: Julia Duerr, Simon Y Graeber, Stefan Oscarson, Marcus A Mall

Förderung

  • NHLBI NIH HHS
  • Bundesministerium für Bildung und Forschung
  • Deutsche Forschungsgemeinschaft
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Addante, A., Raymond, W., Gitlin, I., Charbit, A., Orain, X., Scheffler, A. W., Kuppe, A., Duerr, J., Daniltchenko, M., Drescher, M., Graeber, S. Y., Healy, A. M., Oscarson, S., Fahy, J. V., & Mall, M. A. (2023). A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. European Respiratory Journal, 61(5), 2202022. https://doi.org/10.1183/13993003.02022-2022

Vancouver

Addante A, Raymond W, Gitlin I, Charbit A, Orain X, Scheffler AW, et al. A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases. European Respiratory Journal. 2023;61(5):2202022. doi:10.1183/13993003.02022-2022

BibTeX
@article{Addante2023,
  author = {Addante, Annalisa and Raymond, Wilfred and Gitlin, Irina and Charbit, Annabelle and Orain, Xavier and Scheffler, Aaron Wolfe and Kuppe, Aditi and Duerr, Julia and Daniltchenko, Maria and Drescher, Marika and Graeber, Simon Y and Healy, Anne-Marie and Oscarson, Stefan and Fahy, John V and Mall, Marcus A},
  title = {A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {61},
  number = {5},
  pages = {2202022},
  doi = {10.1183/13993003.02022-2022}
}
Kostenlos starten →